



Universiteit
Leiden
The Netherlands

Safety-efficacy balance of S-ketamine and S-norketamine in acute and chronic pain

Noppers, I.M.

Citation

Noppers, I. M. (2011, September 7). *Safety-efficacy balance of S-ketamine and S-norketamine in acute and chronic pain*. Retrieved from <https://hdl.handle.net/1887/17811>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/17811>

Note: To cite this publication please use the final published version (if applicable).

Chapter 2

Ketamine for the treatment of chronic non-cancer pain

Noppers I, Niesters M, Aarts L, Smith T, Sarton E and Dahan A

Department of Anesthesiology, Leiden University Medical Center,
Leiden, The Netherlands

Expert Opin Pharmacother 2010; 11(14):2417-2429.

Introduction

Worldwide the number of patients affected by chronic pain is growing. Presently, in the US alone, chronic pain affects over 70 million people costing the economy more than 100 billion US\$ per year.¹ Management of chronic pain syndromes is characterized by a trial-and-error approach, with interventions including psychotherapy, physiotherapy, drug treatment (including opioids, anti-depressants, anti-epileptics, NSAIDs, and their combinations) and spinal cord stimulation, often with limited success. Recently, the importance of the *N*-methyl-D-aspartate receptor (NMDAR) in the etiology and perseverance of chronic pain was established.² In chronic pain the NMDAR is activated and upregulated in the dorsal horn of the spinal cord (i.e., sensitization) which causes enhanced signal transmission in the pain circuitry and leads to chronic pain that is often coupled to allodynia and hyperalgesia.^{2,3} Consequently, drugs that block the NMDAR may be able to relieve chronic pain and possibly modulate the underlying disease process. The most studied NMDAR antagonist currently available is ketamine.⁴

Here we will discuss the use of low-dose ketamine in the treatment of chronic non-cancer pain, reviewing the complete ketamine database and highlighting recent clinical and preclinical studies (published after 2008). While ketamine was initially marketed as anesthetic agent it recently began its second life in the treatment of chronic and acute (perioperative) pain.⁵⁻⁹ In chronic pain, ketamine is used in the treatment of cancer and non-cancer pain. A major problem with the use of ketamine is the development of psychotropic side effects, especially when used at high dose, while animal data suggests that high-dose and long-term ketamine infusion may be associated with neurotoxicity.⁷

Recent studies (published after 2008), focusing on long-term infusion of low-dose ketamine in the treatment of chronic non-cancer pain, demonstrated efficacy and safety of the ketamine infusion, although the patients were not followed for > 3 months.¹⁰⁻¹² Previous reviews have addressed the efficacy of ketamine in acute pain, cancer pain and chronic non-cancer pain (covering studies until 2008), predominantly of studies employing short-term administration paradigms.⁵⁻⁸

Chemistry

Ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone) is an arylcycloalkylamine molecule, a phenylpiperidine derivative, structurally related to phencyclidine (PCP). It was first synthesized in the early 1960s and initially introduced as safer alternative to PCP. In 1965 the anesthetic properties of ketamine became apparent. At anesthetic doses it causes a dissociative anesthetic

state (i.e., dissociation between the thalamus and limbic system) while at subanesthetic doses it is a potent analgesic. Ketamine exists in two stereo-isomeric forms, S(+) and R(-), due to the presence of a chiral center located on C-atom 2 of the cyclohexane ring (Figure 1).⁵ The S(+)-variant has about two and four times greater analgesic potency compared to the racemic mixture and the R(-)-enantiomer, respectively.⁵ There are two different commercial forms of ketamine available: the racemic mixture (Ketalar™, Pfizer Inc.) and in some countries (e.g., The Netherlands, Germany, Austria) the S(+)-enantiomer (S-ketamine or Ketanest-S™, Pfizer Inc.).




Figure 1 left S(+)-ketamine; right R(-)-ketamine. The chiral center © is at C-atom 2 of the cyclohexane ring.

Pharmacokinetics and metabolism

Few studies addressed the pharmacokinetics of ketamine in chronic pain patients using an extended administration paradigm.¹⁰ Studies on the acute (i.e. short-term) administration show limited bioavailability after oral, sublingual and rectal administration (20-30%), partly because of the large first-pass effect, while bioavailability is somewhat higher after intranasal application (45%), with no differences between the two enantiomers of the racemic mixture.¹³ Peak concentration after oral ketamine ingestion is reached after 20-30 min. The pharmacokinetics after a single or short-term infusion have well been described; volume of distribution, distribution and elimination half-life are 0.3 L/kg, 15 min and 2-3 h, respectively.^{14,15} After intravenous infusion of the racemic mixture, the R(-)-enantiomer inhibits the elimination of the S(+)-variant (magnitude of effect about 30%).¹⁶ Furthermore, for the S(+)-enantiomer a sex difference in pharmacokinetics has been observed with a 20% greater clearance in women.¹⁵

Ketamine rapidly passes the blood-brain barrier due its high lipophilicity (blood-effect-site equilibration half-life 1-3 min), ensuring a rapid onset of analgesic effect.^{15,17}

Ketamine is extensively metabolized by the hepatic cytochrome P450 enzyme system (by CYP3A4, CYP2B6 and CYP2C9 enzymes).^{18,19} The main pathway is *N*-demethylation to norketamine with subsequent metabolism of norketamine into 6-hydroxynorketamine. Norketamine and the hydroxy-product are glucuronidated and eliminated via the kidney and bile.^{20,21} Induction of the CYP system will have limited effect on the ketamine concentration as its hepatic clearance before induction is high and approaches liver blood flow (1 L/min).¹⁵ Drugs that inhibit CYP enzymes involved in ketamine's metabolism (such as clarithromycin), will increase ketamine plasma concentrations, in particular after oral administration.²² Norketamine appears within minutes in plasma after the intravenous administration of ketamine, and, particularly after long-term infusions, reaches values similar or even greater than that of ketamine.^{10,15,17} Upon the termination of ketamine infusion, the plasma concentrations drop rapidly and norketamine concentrations exceed ketamine concentrations.^{10,15,17}

Mechanism of action

While ketamine acts at multiple receptor systems (such as the μ -opioid receptor and the HCN1 pacemaker cell), the analgesic effect of ketamine in chronic pain is attributed to its effects at the NMDAR.^{2,10,23,24} The NMDAR is an excitatory ionotropic glutamate receptor present in the spinal cord and the brain. In the resting state the receptor is blocked by Mg^{2+} ions. The block is lost upon strong and sustained nociceptive activation of the receptor by presynaptic release of glutamate (in the presence of co-agonist glycine). This results in a neuronal influx of positive ions (Na^+ , Ca^{2+}) and an increase in discharge of dorsal horn nociceptive neurons (causing enhanced pain perception). Prolonged activation of the NMDAR results in plastic changes in the spinal cord with upregulation of NMDAR and central sensitization leading to the chronification of pain.^{2,3,25} Ketamine is a non-competitive antagonist of the NMDAR, reverting the NMDAR to its resting state and consequently causing the impairment of nociceptive signal propagation to the brain and, especially after long-term administration, restoration of the physiological balance between pain inhibition and facilitation.¹⁰ Of further interest is that ketamine's metabolite norketamine is a non-competitive antagonist of the NMDA receptor.²⁶ Animal data indicate that norketamine passes the blood-brain barrier, has about one-third the potency of ketamine, and is thought to be involved in ketamine's analgesic effect as well as (though to a lesser extent) the development of psychotropic side effects.²⁶ No data are presently available to substantiate this in humans.

Clinical efficacy

Randomized clinical trials: 1992-2010

Most studies published on the effect of ketamine on chronic pain are open-label studies, case series or case reports. We searched seven electronic databases (PubMed, EMBASE, Web of Science, the Cochrane Library, CINAHL, PsychINFO and Academic Search Premier) in June 2010 for papers assaying ketamine's analgesic effect in chronic pain patients using a prospective, randomized, controlled design (Key words included pain, chronic pain, chronic disease, neuralgia, neuropathic pain, complex regional pain syndrome, fibromyalgia, neuropathic pain, neuropathy, low back pain, diabetic neuropathy, migraine, multiple sclerosis, postherpetic neuralgia, trigeminal neuralgia, phantom limb, ketamine, S-ketamine, ketanest, ketalar, ketaset, calipsol, kalipsol, calypsol, 2-(2-Chlorophenyl)-2-(methylamino)-cyclohexanone, CI 581. Limits included human, English, French, German and Dutch).

We retrieved 36 RCTs (first publication date 1992, 6 published after 2008) of which the majority (21) were on iv ketamine (20 using the racemic mixture, 1 S-ketamine).^{10-12,27-61} See tables 1 and 2 for the study characteristics.

The infusion duration of ketamine in studies on iv administration varied from single injections to multiple day infusions (max. infusion duration 2 weeks) with large variations in doses (Tables 1 and 2). We refrained from performing a meta-analysis as the heterogeneity between studies was large and the quality of the majority of studies poor to moderate (most studies did not present the method of randomization, refrained from stating how dropouts and withdrawals were taken into account, did not present information on allocation concealment). Furthermore, various studies did not give quantitative data on the ketamine analgesic effect and some studies were ended prematurely.

The number of studies that we graded as good^{10,11} were insufficient to perform a meta-analysis. Hence we decided to perform a semi-quantitative analysis on the effect of intravenous infusion duration on treatment effect (magnitude and duration). We included studies that tested the effect of at least 0.15 mg/kg ketamine on chronic pain intensity (Figure 2).

Table 1 Randomized controlled trials on the effect of intravenous ketamine on chronic pain (in chronological order).

Ref	Year	N*	Chronic pain disease	Cross over	Design and treatment	Results
11	2010	20	Neuropathic pain from SCI		20 patients received 80 mg KET infusion in 5 h for 1 week + 3 times/day gabapentin vs 20 patients received a PLCB infusion + 3 times/day gabapentin	Ketamine caused effective analgesia in weeks 1 and 2 following treatment
12	2009	9	Complex regional pain syndrome		KET 4-h infusion (n = 9) vs PLCB (n = 10) infusions for 10 days. Max. infusion = 0.35 mg/kg/h	KET NRS from 7.66 to 6.13 (P < 0.05 at week 3-4) vs PLCB NRS from 7.7 to 7.5. Other pain indices improved for at least 12 weeks
10	2009	30	Complex regional pain syndrome		4.2 day S-KET infusion (increasing dose, max. 20 mg/h, n = 30) vs PLCB (n = 30)	KET caused analgesic effects lasting up to 11 weeks. Maximum effect during treatment week
49	2007	20	Whiplash	+	4 treatment combinations: PLCB/PLCB, PLCB/remifentanyl, KET/PLCB, KET/remifentanyl. iv TCI system with target KET concentration of 100 ng/ml. Infusion duration 65 min	KET/PLCB and KET/remifentanyl reduced VAS scores from 3.9 to 1.8 and 3.5 to 1.0 cm (P < 0.001) during infusion
40	2006	20	Nerve injury pain	+	0.24 mg/kg KET over 30 min vs lidocaine (5 mg/kg) vs PLCB	Spontaneous pain reduction by KET only; evoked pain reduced by both drugs
48	2005	30	Whiplash	+	0.3 mg/kg KET infusion vs 0.3 mg/kg morphine vs 5 mg/kg lidocaine vs PLCB. Infusion duration 30 min	KET = 14 responders; duration of effect no longer than 1-1.5 h
46	2004	10	SCI and neuropathic pain below the level of injury	+	KET 0.4 mg/kg injection vs lidocaine 2.5 mg/kg vs PLCB	KET responders 5/10 vs 1/10 after lidocaine and 0/10 after PLCB. KET effect = 38% VAS reduction (lidocaine = 10% and PLCB = 3%, P = 0.01)
44	2003	12	Chronic neuropathic pain	+	KET iv 60 µg/kg bolus + 6 µg/kg/min for 20 min vs alfentanil vs PLCB	KET (and alfentanil) produced significant reductions of pain and hyperalgesia but not cold pain detection threshold
45	2003	12	Peripheral neuropathic pain of traumatic origin	+	Singe KET 0.4 mg/kg injection vs lidocaine 2.5 mg/kg vs PLCB	KET response in 7/12 patients: KET caused a 55% reduction in VAS vs 34% and 22% for lidocaine and PLCB (P = 0.009)

54	2002	18	Painful limb ischemia		KET infusion + opioid vs PLCB infusion + opioid. KET dose 0.6 mg/kg infused over 4 h	Improved pain relief by KET of 65% 1 day post-treatment and 69% 5 days post-treatment. Also significant effects on general activity and quality of life KET reduced hyperalgesia
50	2001	12	Post-nerve injury	+	KET TCI concentration 50, 100 and 150 ng/ml vs alfentanil (TCI 25, 50 and 75 ng/ml) vs PLCB	
41	2000	29	Fibromyalgia	+	0.3 mg/kg KET over 30 min vs PLCB in 29 patients	17/29 patients showed pain relief > 50%
58	1998	8	Pain from arteriosclerosis of the lower extremities	+	KET bolus injection 0.15, 0.30 or 0.45 mg/kg vs morphine 10 mg bolus injection	Dose dependent analgesic effect from KET with greater effect than morphine at 0.3 and 0.45 mg/kg
60	1997	18	Fibromyalgia	+	KET 0.3 mg/kg infusion over 30 min vs PLCB vs 0.3 mg/kg morphine vs 5 mg/kg lidocaine	KET responders = 8, non responders = 8. Effect in responders 1-5 days
56	1997	81	Chronic migraine with a temporal pattern	+	KET infusion 0.15-1 mg/kg per 24 h for 2 weeks vs PLCB	Chronic migraine became episodic in 76/81 patients with a reduction of intake of co-analgesics
57	1996	11	Phantom limb pain	+	KET 0.1 mg/kg bolus injection followed by 7 µg/kg/min for max. 45 min. vs PLCB	KET reduced stump and phantom pain by 100%
36	1995	10	Peripheral neuropathic pain	+	KET (0.2 mg/kg bolus + 0.3 mg/kg over 1 h) vs magnesium (bolus + cont. infusion)	KET produced a 57% reduction of pain and 33% reduction of area of allodynia
53	1995	8	Chronic posttraumatic pain and widespread mechanical allodynia	+	KET infusion for 2 h (mean dose 58 mg) vs alfentanil (11 mg) vs PLCB	Pain relief: KET 65%, alfentanil 46%, PLCB 22% (P < 0.01). Similar observations for relief of allodynia. Pain relief disappeared upon end of infusion
29	1994	6	Chronic neuropathic pain (central pain, peripheral neuropathy)	+	Single or series of 0.25 mg/kg KET injections vs PLCB	5/6 patients had pain relief lasting 2-3 h, 1 had 2 weeks effect; 1 patient showed no effect
34	1994	8	Post herpetic neuralgia	+	Single 0.15 mg/kg KET injection vs morphine (0.075 mg/kg) or PLCB	Pain relief by KET (but not morphine or placebo)
35	1994	9	Spinal cord injury	+	KET (0.06 mg/kg bolus + 6 µg/kg/h for 20 min) vs alfentanil vs PLCB	Pain relief by KET of 40% (and alfentanil of 20%)

N* = number of patients receiving ketamine, **KET** = ketamine, **NRS** = numerical rating scale, **PLCB** = placebo, **SCI** = spinal cord injury, **S-KET** = S-ketamine, **TCI** = target controlled intravenous infusion, **VAS** = visual analogue score.

Table 2 Randomized controlled trials on the effect of non-intravenous ketamine on chronic pain (in chronological order).

Ref	Year	N*	Chronic pain disease	Cross over	Design and treatment	Results
30	2010	101	Chemotherapy-induced neuropathy		Topical. KET-amitriptyline-baclofen cocktail (n = 101) vs PLCB (n =104)	No effect on pain relief greater than placebo
43	2010	16	Chronic neuropathic pain		Intranasal. low dose 0.2 mg/kg, n = 8 and high dose 0.4 mg/kg, n = 8	Pain scores decreased with max. effect at t = 60 min. No effect on QST
37	2009	20	Complex regional pain syndrome	+	Topical. KET (10% in organogel) vs PLCB	KET caused reduction of allodynia and hyperalgesia
27	2008	18	Temporomandibular joint arthralgia	+	Intraarticular. 18 patients received one injection with KET or saline	No effect on pain or somatosensory end-points
32	2008	14	Chronic myofascial pain in temporomandibular disorder	+	IM. injection of KET or PLCB in m. masseter	No relief of spontaneous pain
52	2005	45	Neuropathic pain patients with allodynia, hyperalgesia or pinprick hypesthesia		Topical. 4 Groups: PLCB (n = 25), 2% amitriptyline (n = 22), 1% KET (n =22), 1% KET + 2% amitriptyline (n = 23)	Effects no larger than PLCB
61	2005	22	Central neuropathic pain		Iontophoresis. KET 50 mg (n = 11) vs 75 mg (n = 11) per day for 1 week vs PLCB (n = 11)	No effect on pain scores from KET but 75 mg improved quality of life and health status
31	2004	20	Breakthrough pain in chronic pain patients (n = 16) and cancer patients (n = 4)	+	Intranasal. KET 10-50 mg (1-5 sprays) vs PLCB (1-5 sprays)	KET produced analgesia within 10 min lasting at least 1 h. Max effect occurred after 40 min (NRS change = 3.13. vs PLCB = 0.8, P = 0.0001)
51	2003	20	Chronic neuropathic pain	+	Topical. KET for 2-days: 0.5% KET vs 1% amitriptyline vs 0.5% KET + 1% amitriptyline vs PLCB	Effects no larger than PLCB

47	2002	10	Chronic neuropathic pain	<p>Epidural. KET (0.3 mg/kg/day) + lidocaine (n = 10) vs epidural clonidine (90 µg/day) + lidocaine (n = 13) using PCEA device. Treatment duration 3 weeks</p> <p>Oral. KET syrup 0.5 mg/kg vs PLCB every 6 h for 1 week</p> <p>IM. Study A: KET 0.4 mg/kg vs pethidine 1 mg/kg Study B: KET 4 mg/kg vs PLCB for 3 days</p> <p>Oral. N = 1 trial in 9 patients: KET 10 mg once/day for 6 weeks vs PLCB</p> <p>SC. 80 µg/kg in acute sufferers and 80 µg/kg 3 times daily in chronic sufferers for 3 weeks</p>	<p>Significant reductions in pain intensity (VAS) in both groups from 9 to 2 cm. Effect persisted for 2-5 weeks following epidural catheter removal KET caused pain relief: VAS from 78 to 49 mm</p> <p>Study A. KET: 9/26 no effect; 9/26 effect 1 h; 8/26 effect > 12 h. Study B. 5/26 had an analgesic effect</p>	
38	2002	8	Chronic neuropathic pain	+		
59	1999	26	Trigeminal neuropathic pain	+		
42	1999	21	Chronic neuropathic pain			
55	1995	34	Acute migraine (n = 17), Chronic episodic migraine (n = 17)	+		
39	1992	20	Whiplash, postdiscoidectomy, chronic back-ache			<p>Intraligamentous. injection with 0.25 mg/kg ketamine vs 2% lidocaine</p> <p>VAS reduced from 8 to 2 after KET with increased functionality (no effect of lidocaine)</p>

N* = number of patients receiving ketamine, **IM** = intramuscular, **KET** = ketamine, **NRS** = numerical rating scale, **PCEA** = patient controlled epidural anesthesia, **PLCB** = placebo, **QST** = quantitative sensory testing, **SC** = subcutaneous, **VAS** = visual analogue score.




Figure 2 Semi-quantitative analysis on the effect of infusion duration on intravenous ketamine analgesic efficacy. Randomized controlled trials that infused at least 0.15 mg/kg were included in the analysis. On the x-axis infusion duration in hours, on the y-axis effect defined as follows: no analgesic effect (effect = 0), a reduction in pain intensity no greater than 50% of pre-treatment pain during infusion (effect = 1), a reduction in pain intensity greater than 50% of pre-treatment pain during infusion (effect = 2) and a significant reduction in pain intensity with pain relief persisting for at least 48 h following the termination of infusion (effect = 3). Each filled circle is one study. The continuous line is the result of a logistic regression analysis. The open square is the ID50 or infusion duration causing a median analgesic effect (in the current set of studies a median effect = 2.25 was estimated). ID50 = 1.7 ± 0.8 h (median \pm SEM) in a dose range of 0.15-0.5 mg/kg. At infusion duration > 10 h the probability of an effect lasting > 48 h approaches 95%, while at durations > 30 h the probability approaches 99%.

The results show that the majority of studies demonstrate a more than 50% reduction of pain intensity, but the effect did not persist beyond the 48 h following infusion. The infusion duration of these studies ranged from 30 min to 2 h. Only four studies reported an analgesic effect persisting beyond the 48 h following infusion, three of which (all published after 2008) employed long-term infusion schemes (4.2 days continuous to daily 4-h infusions for 10 days, with a dose range of 16 to 25 mg/h).¹⁰⁻¹² Our analysis indicates that at an infusion duration > 10 h the probability of an effect lasting > 48 h approaches 95%, while at durations > 30 h the probability approaches 99% (Figure 2). Note, however, that following infusion analgesia slowly dissipates over time (see, for example, Figure 3).^{10,11} This indicates that these infusion paradigms were insufficient to cause a permanent reduction of pain. Possibly other infusion regimes (e.g. regular 10-h infusions, daily 1- to 2-h infusions) may have a more permanent effect. None of the published RCTs addressed this issue.

Randomized clinical trials on long-term intravenous infusion: 2009-2010

Three RCTs on iv ketamine published after 2008 were identified¹⁰⁻¹²; all used a multiple day infusion scheme. The most recent study by Amr is on the effect of ketamine in spinal cord injury related chronic pain.¹¹ Group 1 (n = 20) received 80 mg intravenous ketamine over 5 h daily for one week, plus 300 mg gabapentin three times daily; Group 2 (n = 20) received a 5-h placebo infusion once daily, plus 300 mg gabapentin three times daily. Pain relief was significantly greater in Group 1 relative to Group 2 during infusion and during the first 2 weeks following infusion. Thereafter, there were no more differences between treatment groups in pain scores, although pain scores remained decreased versus baseline for at least 4 weeks following the end of treatment in both groups. Ketamine-related side effects occurred in 3/20 patients (short-lasting delusions). None of the side effects required intervention. We consider this a qualitatively good study that may lead the way to outpatient treatment of chronic pain patients with intravenous ketamine.

Schwartzman et al. assessed the effect of daily 4-h iv ketamine infusions (max. dose = 0.35 mg/kg/h) for 10 days in Complex Regional Pain Syndrome (CRPS) chronic pain patients.¹² Subjects in both arms of the study received clonidine and midazolam. The subjects receiving ketamine had consistent decreases for all pain-related parameters that lasted for the 12-week post-treatment evaluation period (total McGill pain score pre-treatment = 23.1, post-treatment weeks 1-2 = 16.2, post-treatment weeks 3-4 = 13.4 and post-treatment weeks 9-12 = 15.4). Ketamine-related side effects included nausea, headache, tiredness and dysphoria. This study was criticized for reasons of early termination, small sample size, and relatively limited analgesic effect.⁶² While powered to study 20 patients per arm, the study was stopped after 9 patients were enrolled in the ketamine arm and 10 in the placebo arm. The reasons given for the premature end of the trial were that the authors had seen greater pain relief with a higher dose of ketamine than allowed in the protocol (max. dose 25 mg/h) and the absence of a placebo effect. Note, however, that these greater analgesic responses were based on an open-label study.⁶²

Sigtermans et al. studied the effect of iv ketamine in CRPS patients with moderate to severe chronic pain.¹⁰ Thirty patients (disease duration: mean 7.4 years, range 0.1-32 years; mean baseline pain score 7.2 on a scale of 0-10) were treated with a 4.2 day continuous infusion of ketamine's S(+)-enantiomer with a mean dose of 20 mg/h. Significant analgesic effects were observed in the 4.2 day-treatment phase of the study (pain score 2.7 versus 5.5). Over the 12-week duration of the study ketamine modulated the course of chronic pain more favorably than placebo (Figure 3).




Figure 3 Results of the Sigtermans et al. trial on a 4.2-day continuous intravenous ketamine infusion in 60 patients with complex regional pain syndrome chronic pain. The results of the randomized trial are given (squares: ketamine data, open circles: placebo data) showing a 12-week significant effect on pain intensity scores ($P < 0.001$). Twenty subjects initially receiving placebo returned to receive open-label ketamine (closed circles). The black bar indicates the infusion period. NRS = numerical rating scale. Adapted from reference 10.

Ketamine-related side effects included nausea/vomiting and psychotropic effects. Although this study is considered qualitatively “good”, points of critique include the absence of improvement of function and the cost of the intensive and long-term in-house treatment.^{62,63} Twenty patients that initially had received placebo were allowed to receive the identical ketamine treatment, but now in an open-label fashion. As expected, their analgesic responses were larger by at least 1 NRS point at 2 weeks and pain relief $> 50\%$ lasted for more than 3 weeks (Figure 3). This suggests that a large part of the responses seen in this patient group is expectancy-related.

Safety and tolerability

Ketamine causes a variety of dose-dependent side effects ranging from nausea/vomiting, sedation, vertigo, tachycardia, hypertension to increased cardiac output.^{7,10,15,64} Recent discussions indicate that three important issues regarding safety and tolerability of ketamine are of concern⁶²: the occurrence of psychotropic side effects; possible neurotoxicity; and the abuse potential of repeated or long-term ketamine use.

Cardiovascular side effects

The effects of ketamine on the cardiovascular system are related to activation of the sympathetic system (ketamine causes the systemic release of catecholamines and inhibition of norepinephrine re-uptake at peripheral nerves and non-neuronal tissues such as the myocardium).⁶⁴ At the doses used in the treatment of chronic pain the effects on cardiovascular system seem moderate and well tolerated. However, care is always required in patients with cardiovascular disease (e.g., patients with ischemic heart disease and hypertension).

Psychotropic side effects and abuse potential

After intravenous dosing psychotropic side effects are common ranging from 'drug high' to derealization/depersonalization, hallucinations and fear/panic attacks. These symptoms resemble psychotic episodes in schizophrenia, but disappear rapidly upon the termination of the infusion.^{10,65} These effects are dose dependent.⁶⁶ Patient compliance with psychotropic symptoms is variable. When unacceptable psychotropic effects occur, the ketamine infusion rate may be lowered or a benzodiazepine or α 2-adrenergic receptor agonist (clonidine, dexmedetomidine, neuroleptics, antiepileptics) may be added.⁶⁷ During prolonged infusions the occurrence and severity of psychotropic effects seems to decline over time. However, the psychotropic effects may cause the patient to abandon further treatment.¹⁰ In our experience there are no differences in occurrence of psychotropic side effects during treatment with the racemic mixture or the S(+)-enantiomer.

Ketamine is a drug of abuse and increasingly used for recreational use (mostly by sniffing ketamine powder known as Special K or Vitamin K).⁶⁸ Side effects related to the chronic use of ketamine are cognitive dysfunction (memory deficits) and mild psychotic attacks (e.g., flashbacks) occurring up to weeks after the intake.⁶⁹ In animals regular ketamine use has been associated with typical addictive behaviour.⁷⁰

Neurotoxicity

Animal studies show that under specific circumstances and in specific areas of the brain NMDAR antagonists, including (high-dose) ketamine, have neuroprotective effects, while under other circumstances these same agents are neurotoxic.^{67,71,72} Neuronal injury (vacuolization in neurons and apoptotic neurodegeneration) is caused by loss of inhibition of inhibitory pathways leading to the enhancement of excitatory neuronal activity. Several drugs are able to prevent neuronal injury from NMDAR antagonists, including benzodiazepines and α 2-agonists.⁷³ Despite the observation in animals, ketamine is still widely used in humans, partly because no data in humans are available that cause concern about neurotoxicity

(“no hint of a suggested association between ketamine and brain damage or learning delay, the presumed sequelae of neuroapoptosis, has been reported”)⁷⁴ and the fact that most infusions are combined with either a benzodiazepine or an α 2-agonist.

Summary and conclusions

Worldwide the number of patients affected by chronic pain is growing and conventional treatment is often insufficient.¹ Recently the importance of the NMDAR in the etiology and maintenance of chronic pain has been established. Of all available NMDAR antagonists ketamine is the most potent and consequently has been applied in the treatment of various chronic pain syndromes. Most frequently studied is the intravenous route of administration followed by topical, oral and intranasal routes.

The majority of RCTs on intravenous ketamine published since 1992 indicate that when applying short-term infusions (< 4 h) chronic pain is reduced by about 50% irrespective of the dose given, but the effect dissipates rapidly upon the termination of infusion. Three recent studies¹⁰⁻¹² (published in 2009 and 2010) on long-term (days to weeks) ketamine administration (mean infusion rate 20 mg/h) show that the duration of effect lasts multiple weeks, although a slow return to pretreatment pain scores is observed in all studies. In none of the studies a full effect of ketamine on pain or any effect on function or quality of life has been detected, possibly due to the fact that none of the studies was properly powered to study these latter end-points. Evidently, further RCTs of good quality are required before any conclusion may be drawn on the efficacy of ketamine, specifically of long-term ketamine infusions, on long-term pain relief in chronic pain patients.

In most RCTs, various side effects were noted. Most worrisome side effects to the patients are psychotropic in nature (ranging from ‘drug-high’ to panic/fear and hallucinations) that may be prevented/treated by co-administration of benzodiazepines and/or α 2-adrenergic receptor agonists. Other side effects include nausea/vomiting, sedation and hypertension/tachycardia. The latter symptoms are related to ketamine’s activation of the sympathetic system and seem of minor importance at low-infusion rates. Finally, there is concern for the possibility of neurotoxicity and potential for abuse from long-term or repetitive ketamine use. Although indications for these concerns were derived from animal studies at relatively high ketamine dose, these issues remain understudied in humans.

The expert's opinion

Ketamine's use as an anesthetic and analgesic in the treatment of acute pain is driven by its pharmacokinetics (i.e., upon the termination of infusion anesthesia and analgesia dissipate rapidly).^{12,14} In contrast, long-term (days to weeks) continuous or repetitive infusion of low-dose ketamine results in pain relief persisting for weeks following treatment.^{9,24,58} This suggests that ketamine has a disease modulatory role and initiates a cascade of events of which the first step is probably desensitization in instances where NMDAR sensitization is an important factor in the process of the development and chronification of pain. This effect of ketamine in the chronic pain process is exceptional and different from most other analgesic agents that do not have the ability to interfere with the process of central sensitization. Despite these promising results ketamine is not (yet) viable as routine treatment for chronic pain.

Several important issues have to be resolved. First, safety/toxicity studies in humans aimed at cognitive (e.g. memory deficits) and long-term effects of ketamine, as well as studies on ketamine's abuse liability, are needed. Second, administration modes allowing outpatient treatment have to be developed and tested. This will not only be less costly compared to multiple-day in-patient treatment, but will allow the patient to be treated in his/her own surroundings. Finally, safe dosing schemes need to be developed that ensure persistent relief of pain. When these issues have been resolved satisfactorily, ketamine may gain a prominent place in the treatment of chronic pain.

References

1. Dahan A, Bauer M, Sarton E, Sigtermans M, van Hilten J and Marinus J. What is considered long-term pain relief in chronic pain management? Re: Sigtermans et al. *Pain* 2010; 149(2):410-411.
2. Chizh BA. Low dose ketamine: a therapeutic and research tool to explore *N*-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. *J Psychopharmacol* 2007; 21(3):259-271.
3. Kalia LV, Kalia SK and Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. *Lancet Neurol* 2008; 7(8):742-755.
4. Childers WE Jr and Baudy RB. *N*-methyl-D-aspartate antagonists and neuropathic pain: the search for relief. *J Med Chem* 2007; 50(11):2557-2562.
5. Hocking G and Cousins MJ. Ketamine in chronic pain management: an evidence-based review. *Anesth Analg* 2003; 97(6):1730-1739.
6. Himmelseher S and Durieux ME. Ketamine for perioperative pain management. *Anesthesiology* 2005; 102(1):211-220.
7. Bell RF. Ketamine for chronic non-cancer pain. *Pain* 2009; 141(3):210-214.
8. Blonk MI, Koder BG, van den Bemt PM and Huygen FJ. Use of oral ketamine in chronic pain management: a review. *Eur J Pain* 2010; 14(5):466-472.

9. Neil MJE. Survey on the use of ketamine infusions in Scottish hospitals. *Pain News* 2008;(Summer):36-37.
10. Sigtermans MJ, van Hilten JJ, Bauer MCR, Arbous MS, Marinus J, Sarton EY and Dahan A. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. *Pain* 2009; 145(3):304-311.
11. Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. *Pain Physician* 2010; 13(3):245-249.
12. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E and Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. *Pain* 2009; 147(1-3):107-115.
13. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y and Iga T. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. *Biopharm Drug Dispos* 2003; 24(1):37-43.
14. Miller RD, Afton-Bird G and Fleisher LA. *Miller's anesthesia*. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2004.
15. Sigtermans M, Dahan A, Mooren R, Bauer M, Kest B, Sarton E and Olofsen E. S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. *Anesthesiology* 2009; 111(4):892-903.
16. Ihmsen H, Geisslinger G and Schuttler J. Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. *Clin Pharmacol Ther* 2001; 70(5):431-438.
17. Sigtermans M, Noppers I, Sarton E, Bauer M, Mooren R, Olofsen E and Dahan A. An observational study on the effect of S(+)-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. *Eur J Pain* 2010; 14(3):302-307.
18. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y and Iga T. Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. *Drug Metab Dispos* 2001; 29(6):887-890.
19. Hijazi Y and Bouliou R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. *Drug Metab Dispos* 2002; 30(7):853-858.
20. Leung LY and Baillie TA. Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. *J Med Chem* 1986; 29(11):2396-2399.
21. Woolf TF and Adams JD. Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations. *Xenobiotica* 1987; 17(7):839-847.
22. Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ and Olkkola KT. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. *Eur J Pain* 2010; 14(6):625-629.
23. Sarton E, Teppema LJ, Olievier C, Nieuwenhuijs D, Matthes HW, Kieffer BL and Dahan A. The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. *Anesth Analg* 2001; 93(6):1495-1500.
24. Chen X, Shu S and Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. *J Neurosci* 2009; 29(3):600-609.
25. Petrenko AB, Yamakura T, Baba H and Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. *Anesth Analg* 2003; 97(4):1108-1116.
26. Holtman JR Jr, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M and Wala EP. Effects of norketamine enantiomers in rodent models of persistent pain. *Pharmacol Biochem Behav* 2008; 90(4):676-685.
27. Ayesh EE, Jensen TS and Svensson P. Effects of intra-articular ketamine on pain and somatosensory function in temporomandibular joint arthralgia patients. *Pain* 2008; 137(2):286-294.
28. Baad-Hansen L, Juhl GI, Jensen TS, Brandsborg B and Svensson P. Differential effect of intravenous S-ketamine and fentanyl on atypical odontalgia and capsaicin-evoked pain. *Pain* 2007; 129(1-2):46-54.

29. Backonja M, Arndt G, Gombar KA, Check B and Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. *Pain* 1994; 56(1):51-57.
30. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD III, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr, Riepl M, Christensen B and Loprinzi CL. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. *Support Care Cancer* 2011; 19(6):833-841.
31. Carr DB, Goudas LC, Denman WT, Brookoff D, Staats PS, Brennen L, Green G, Albin R, Hamilton D, Rogers MC, Firestone L, Lavin PT and Mermelstein F. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. *Pain* 2004; 108(1-2):17-27.
32. Castrillon EE, Cairns BE, Ernberg M, Wang K, Sessle BJ, Arendt-Nielsen L and Svensson P. Effect of peripheral NMDA receptor blockade with ketamine on chronic myofascial pain in temporomandibular disorder patients: a randomized, double-blinded, placebo-controlled trial. *J Orofac Pain* 2008; 22(2):122-130.
33. Eichenberger U, Neff F, Svetcic G, Bjorgo S, Petersen-Felix S, Arendt-Nielsen L and Curatolo M. Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. *Anesth Analg* 2008; 106(4):1265-1273.
34. Eide PK, Jorum E, Stubhaug A, Bremnes J and Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. *Pain* 1994; 58(3):347-354.
35. Eide PK, Stubhaug A and Stenehjem AE. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. *Neurosurgery* 1995; 37(6):1080-1087.
36. Felsby S, Nielsen J, Arendt-Nielsen L and Jensen TS. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. *Pain* 1996; 64(2):283-291.
37. Finch PM, Knudsen L and Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: A double-blind placebo-controlled trial of topical ketamine. *Pain* 2009; 146(1-2):18-25.
38. Furuhashi-Yonaha A, Iida H, Asano T, Takeda T and Dohi S. Short- and long-term efficacy of oral ketamine in eight chronic-pain patients. *Can J Anaesth* 2002; 49(8):886-887.
39. Germain H. Use of locally injected sub-anesthetic doses of ketamine in chronic lumbar or cervical pain. *Region Anesth* 1992; 17(Suppl):58.
40. Gottrup H, Bach FW, Juhl G and Jensen TS. Differential effect of ketamine and lidocaine on spontaneous and mechanical evoked pain in patients with nerve injury pain. *Anesthesiology* 2006; 104(3):527-536.
41. Graven-Nielsen T, Aspegren KS, Henriksson KG, Bengtsson M, Sorensen J, Johnson A, Gerdle B and Arendt-Nielsen L. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. *Pain* 2000; 85(3):483-491.
42. Haines DR and Gaines SP. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. *Pain* 1999; 83(2):283-287.
43. Hugel V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D and Azad SC. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. *Eur J Pain* 2010; 14(4):387-394.
44. Jorum E, Warncke T and Stubhaug A. Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine - a double-blind, cross-over comparison with alfentanil and placebo. *Pain* 2003; 101(3):229-235.
45. Kvarnstrom A, Karlsten R, Quiding H, Emanuelsson BM and Gordh T. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. *Acta Anaesthesiol Scand* 2003; 47(7):868-877.
46. Kvarnstrom A, Karlsten R, Quiding H and Gordh T. The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. *Acta Anaesthesiol Scand* 2004; 48(4):498-506.
47. Lauretti GR, Rodrigues ADM, Gomes JMA and Dos-Reis MP. Epidural ketamine versus epidural clonidine as therapeutic for refractory neuropathic chronic pain. *Revista Brasileira de Anestesiologia* 2002; 52(1):34-40.

48. Lemming D, Sorensen J, Graven-Nielsen T, Arendt-Nielsen L and Gerdle B. The responses to pharmacological challenges and experimental pain in patients with chronic whiplash-associated pain. *Clin J Pain* 2005; 21(5):412-421.
49. Lemming D, Sorensen J, Graven-Nielsen T, Lauber R, Arendt-Nielsen L and Gerdle B. Managing chronic whiplash associated pain with a combination of low-dose opioid (remifentanyl) and NMDA-antagonist (ketamine). *Eur J Pain* 2007; 11(7):719-732.
50. Leung A, Wallace MS, Ridgeway B and Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. *Pain* 2001; 91(1-2):177-187.
51. Lynch ME, Clark AJ and Sawynok J. A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. *Clin J Pain* 2003; 19(5):323-328.
52. Lynch ME, Clark AJ, Sawynok J and Sullivan MJ. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. *Anesthesiology* 2005; 103(1):140-146.
53. Max MB, Byas-Smith MG, Gracely RH and Bennett GJ. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. *Clin Neuropharmacol* 1995; 18(4):360-368.
54. Mitchell AC and Fallon MT. A single infusion of intravenous ketamine improves pain relief in patients with critical limb ischaemia: results of a double blind randomised controlled trial. *Pain* 2002; 97(3):275-281.
55. Nicolodi M and Sicuteri F. Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. *Int J Clin Pharmacol Res* 1995; 15(5-6):181-189.
56. Nicolodi M, Del Bianco PL and Sicuteri F. Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse. *Int J Clin Pharmacol Res* 1997; 17(2-3):97-100.
57. Nikolajsen L, Hansen CL, Nielsen J, Keller J, Arendt-Nielsen L and Jensen TS. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. *Pain* 1996; 67(1):69-77.
58. Persson J, Hasselstrom J, Wiklund B, Heller A, Svensson JO and Gustafsson LL. The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans. *Acta Anaesthesiol Scand* 1998; 42(7):750-758.
59. Rabben T, Skjeltbred P and Oye I. Prolonged analgesic effect of ketamine, an *N*-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. *J Pharmacol Exp Ther* 1999; 289(2):1060-1066.
60. Sorensen J, Bengtsson A, Ahlner J, Henriksson KG, Ekselius L and Bengtsson M. Fibromyalgia - are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. *J Rheumatol* 1997; 24(8):1615-1621.
61. Vranken JH, Dijkgraaf MG, Kruijs MR, van Dasselaar NT and van der Vegt MH. Iontophoretic administration of S(+)-ketamine in patients with intractable central pain: a placebo-controlled trial. *Pain* 2005; 118(1-2):224-231.
62. Bell RF and Moore RA. Intravenous ketamine for CRPS: Making too much of too little? *Pain* 2010; 150(1):10-11.
63. Kapural L and Stanton-Hicks M. What is considered long-term pain relief in chronic pain management? Re: Sigtermans et al. *Pain* 2010; 149(2):409-410.
64. Timm C, Linstedt U, Weiss T, Zenz M and Maier C. Sympathomimetic effects of low-dose S(+)-ketamine. Effect of propofol dosage. *Anaesthesist* 2008; 57(4):338-346.
65. Bubenikova-Valesova V, Horacek J, Vrajova M and Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. *Neurosci Biobehav Rev* 2008; 32(5):1014-1023.
66. Tucker AP, Kim YI, Nadeson R and Goodchild CS. Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain. *BMC Anesthesiol* 2005; 5(1):2.

67. Lipton SA. Pathologically activated therapeutics for neuroprotection. *Nat Rev Neurosci* 2007; 8(10):803-808.
68. Curran HV and Monaghan L. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. *Addiction* 2001; 96(5):749-760.
69. Wolff K and Winstock AR. Ketamine: From medicine to misuse. *CNS Drugs* 2006; 20(3):199-218.
70. Trujillo KA, Zamora JJ and Warmoth KP. Increased response to ketamine following treatment at long intervals: implications for intermittent use. *Biol Psychiatry* 2008; 63(2):178-183.
71. Slikker W Jr, Zou X, Hotchkiss CE, Divine RL, Sadovova N, Twaddle NC, Doerge DR, Scallet AC, Patterson TA, Hanig JP, Paule MG and Wang C. Ketamine-induced neuronal cell death in the perinatal rhesus monkey. *Toxicol Sci* 2007; 98(1):145-158.
72. Jevtovic-Todorovic V and Carter LB. The anesthetics nitrous oxide and ketamine are more neurotoxic to old than to young rat brain. *Neurobiol Aging* 2005; 26(6):947-956.
73. Bergman SA. Ketamine: review of its pharmacology and its use in pediatric anesthesia. *Anesth Prog* 1999; 46(1):10-20.
74. Green SM and Cote CJ. Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. *Ann Emerg Med* 2009; 54(2):181-190.

